[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2946765T1 - Tekoči farmacevtski sestavek - Google Patents

Tekoči farmacevtski sestavek

Info

Publication number
SI2946765T1
SI2946765T1 SI201430077A SI201430077A SI2946765T1 SI 2946765 T1 SI2946765 T1 SI 2946765T1 SI 201430077 A SI201430077 A SI 201430077A SI 201430077 A SI201430077 A SI 201430077A SI 2946765 T1 SI2946765 T1 SI 2946765T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
SI201430077A
Other languages
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Rio Alessandra Del
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2946765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of SI2946765T1 publication Critical patent/SI2946765T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201430077A 2014-05-23 2014-05-23 Tekoči farmacevtski sestavek SI2946765T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169753.2A EP2946765B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
SI2946765T1 true SI2946765T1 (sl) 2016-11-30

Family

ID=50774704

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201430077A SI2946765T1 (sl) 2014-05-23 2014-05-23 Tekoči farmacevtski sestavek
SI201530373T SI3145487T1 (sl) 2014-05-23 2015-05-15 Kapljeviti farmacevtski sestavek

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201530373T SI3145487T1 (sl) 2014-05-23 2015-05-15 Kapljeviti farmacevtski sestavek

Country Status (24)

Country Link
US (7) US10426832B2 (sl)
EP (4) EP3050557A1 (sl)
JP (1) JP6334819B2 (sl)
KR (4) KR20210108504A (sl)
CN (2) CN106456538A (sl)
AU (3) AU2015263340B2 (sl)
BR (2) BR122021022508B1 (sl)
CA (2) CA3073703A1 (sl)
CY (1) CY1120681T1 (sl)
DK (2) DK2946765T3 (sl)
ES (3) ES2600488T3 (sl)
HR (2) HRP20161311T1 (sl)
HU (2) HUE029849T2 (sl)
IL (3) IL249115B (sl)
LT (2) LT2946765T (sl)
MX (1) MX361061B (sl)
NZ (1) NZ725360A (sl)
PL (2) PL2946765T3 (sl)
PT (2) PT2946765T (sl)
RS (2) RS55548B1 (sl)
RU (2) RU2020112952A (sl)
SG (3) SG10201806300VA (sl)
SI (2) SI2946765T1 (sl)
WO (1) WO2015177057A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
IN2014MU01248A (sl) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
SI2946765T1 (sl) * 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR20180003452A (ko) * 2016-06-30 2018-01-09 (주)셀트리온 안정한 액체 약제학적 제제
MA47106A (fr) * 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
CA3049857A1 (en) * 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
IT201700004019A1 (it) * 2017-01-16 2018-07-16 Gk Pharma Consultans Sa Composizione comprendente carnitina, colato di sodio, acetato di sodio ed eventualmente argento per uso nel trattamento di psoriasi, vitiligine e rosacea
AU2018236651B2 (en) * 2017-03-16 2020-12-10 Lg Chem, Ltd. Liquid formulation of anti-TNF alpha antibody
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
CA3076423A1 (en) * 2017-09-20 2019-03-28 Alvotech Hf Pharmaceutical formulations for adalimumab
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
BR112021013497A2 (pt) * 2019-01-11 2021-09-14 Samsung Bioepis Co., Ltd. Composição farmacêutica compreendendo anticorpo, dispositivo compreendendo o mesmo e uso do mesmo
AU2020364480A1 (en) * 2019-10-08 2022-03-31 Samsung Bioepis Co., Ltd. Stable liquid composition, method for preparing same, and formulation comprising same
CA3217942A1 (en) * 2021-05-05 2022-11-10 Tyler Brown Ionic liquid formulations for treating inflammatory and autoimmune diseases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
RO123028B1 (ro) 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040197324A1 (en) 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
CA2574828C (en) 2004-07-23 2018-11-13 Genentech, Inc. Crystallization of antibodies or fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5670004B2 (ja) 2005-03-08 2015-02-18 ファイザー・プロダクツ・インク 抗ｃｔｌａ−４抗体組成物
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
AR074196A1 (es) 2008-11-17 2010-12-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EP2427211A4 (en) * 2009-05-04 2013-05-01 Abbott Biotech Ltd STABLE FORMULATIONS WITH HIGH PROTEIN CONCENTRATION OF ANTI-TNF-ALPHA HUMAN ANTIBODIES
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
SG190069A1 (en) * 2010-11-11 2013-06-28 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
DK2726090T3 (da) 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
SG10201609982PA (en) * 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
JP2015519382A (ja) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
CA3153799A1 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
EP2911693A4 (en) 2012-10-25 2016-04-27 Medimmune Llc STABLE, LOW-VISIC ANTIBODY FORMULATION
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CA2889488A1 (en) 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU01248A (sl) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
SI2946765T1 (sl) 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
ES2607489T3 (es) * 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation

Also Published As

Publication number Publication date
KR20170005864A (ko) 2017-01-16
JP2017516846A (ja) 2017-06-22
US10426832B2 (en) 2019-10-01
US20210121566A1 (en) 2021-04-29
US11707524B2 (en) 2023-07-25
EP3050557A1 (en) 2016-08-03
PL3145487T3 (pl) 2018-11-30
IL249115B (en) 2018-12-31
US20210196824A1 (en) 2021-07-01
LT2946765T (lt) 2016-11-25
KR102296766B1 (ko) 2021-09-03
AU2020203119A1 (en) 2020-05-28
EP3145487A1 (en) 2017-03-29
DK2946765T3 (en) 2016-10-31
AU2018220051A1 (en) 2018-09-06
MX361061B (es) 2018-11-23
SG11201608745QA (en) 2016-11-29
HUE029849T2 (en) 2017-04-28
US10729769B2 (en) 2020-08-04
DK3145487T3 (en) 2018-10-01
US20210030871A1 (en) 2021-02-04
CN109248315B (zh) 2021-11-09
RU2719431C2 (ru) 2020-04-17
IL263473A (en) 2019-01-31
CA2946953C (en) 2021-05-18
ES2971213T3 (es) 2024-06-04
RU2016150640A3 (sl) 2018-12-07
AU2018220051B2 (en) 2020-06-04
SG10202000517YA (en) 2020-03-30
IL249115A0 (en) 2017-01-31
ES2600488T3 (es) 2017-02-09
US11712471B2 (en) 2023-08-01
WO2015177057A1 (en) 2015-11-26
BR122021022508B1 (pt) 2023-04-11
HRP20161311T1 (hr) 2016-12-02
IL263473B (en) 2021-05-31
KR20210108504A (ko) 2021-09-02
EP2946765B1 (en) 2016-08-31
RU2016150640A (ru) 2018-06-26
CN106456538A (zh) 2017-02-22
KR20200017553A (ko) 2020-02-18
JP6334819B2 (ja) 2018-05-30
PL2946765T3 (pl) 2017-08-31
EP3476386B1 (en) 2024-01-24
KR20230004960A (ko) 2023-01-06
HRP20181479T1 (hr) 2018-11-02
CA2946953A1 (en) 2015-11-26
CA3073703A1 (en) 2015-11-26
EP3476386A1 (en) 2019-05-01
ES2687600T3 (es) 2018-10-26
US20170196974A1 (en) 2017-07-13
IL282481A (en) 2021-06-30
PT2946765T (pt) 2016-11-10
US20200016268A1 (en) 2020-01-16
CN109248315A (zh) 2019-01-22
BR112016026879A8 (pt) 2021-06-29
EP3145487B1 (en) 2018-08-22
EP2946765A1 (en) 2015-11-25
RU2020112952A (ru) 2020-06-03
US20210322551A1 (en) 2021-10-21
HUE040237T2 (hu) 2019-02-28
CY1120681T1 (el) 2019-12-11
BR112016026879A2 (pt) 2017-08-15
AU2015263340B2 (en) 2018-08-09
EP3476386C0 (en) 2024-01-24
AU2015263340A1 (en) 2016-11-03
MX2016015304A (es) 2017-02-22
LT3145487T (lt) 2018-09-25
US20210308262A1 (en) 2021-10-07
NZ725360A (en) 2019-09-27
SG10201806300VA (en) 2018-08-30
RS57780B1 (sr) 2018-12-31
RS55548B1 (sr) 2017-05-31
PT3145487T (pt) 2018-10-19
SI3145487T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
IL277241A (en) A liquid pharmaceutical preparation
ZA201901736B (en) Liquid pharmaceutical composition
HK1257026A1 (zh) 液體藥物組合物
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
HUE048357T2 (hu) Pemetrexedet tartalmazó folyékony gyógyszerészeti kompozíció
HK1244685A1 (zh) 液體藥物組合物
IL253572A0 (en) A liquid pharmaceutical preparation